Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Evaluation of IgE Antibodies to Omalizumab (Xolair®) and Their Potential Correlation to Anaphylaxis.

Baker DL, Nakamura GR, Lowman HB, Fischer SK.

AAPS J. 2016 Jan;18(1):115-23. doi: 10.1208/s12248-015-9821-x. Epub 2015 Sep 4.

2.

Probody therapeutics for targeting antibodies to diseased tissue.

Polu KR, Lowman HB.

Expert Opin Biol Ther. 2014 Aug;14(8):1049-53. doi: 10.1517/14712598.2014.920814. Epub 2014 May 20.

PMID:
24845630
3.

Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index.

Desnoyers LR, Vasiljeva O, Richardson JH, Yang A, Menendez EE, Liang TW, Wong C, Bessette PH, Kamath K, Moore SJ, Sagert JG, Hostetter DR, Han F, Gee J, Flandez J, Markham K, Nguyen M, Krimm M, Wong KR, Liu S, Daugherty PS, West JW, Lowman HB.

Sci Transl Med. 2013 Oct 16;5(207):207ra144. doi: 10.1126/scitranslmed.3006682.

4.

A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life.

Yeung YA, Wu X, Reyes AE 2nd, Vernes JM, Lien S, Lowe J, Maia M, Forrest WF, Meng YG, Damico LA, Ferrara N, Lowman HB.

Cancer Res. 2010 Apr 15;70(8):3269-77. doi: 10.1158/0008-5472.CAN-09-4580. Epub 2010 Mar 30.

5.

Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys.

Deng R, Loyet KM, Lien S, Iyer S, DeForge LE, Theil FP, Lowman HB, Fielder PJ, Prabhu S.

Drug Metab Dispos. 2010 Apr;38(4):600-5. doi: 10.1124/dmd.109.031310. Epub 2010 Jan 13.

6.

Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates.

Yeung YA, Leabman MK, Marvin JS, Qiu J, Adams CW, Lien S, Starovasnik MA, Lowman HB.

J Immunol. 2009 Jun 15;182(12):7663-71. doi: 10.4049/jimmunol.0804182.

7.

Technology comparisons for anti-therapeutic antibody and neutralizing antibody assays in the context of an anti-TNF pharmacokinetic study.

Loyet KM, Deng R, Liang WC, Wu Y, Lowman HB, DeForge LE.

J Immunol Methods. 2009 Jun 30;345(1-2):17-28. doi: 10.1016/j.jim.2009.03.012. Epub 2009 Apr 2.

PMID:
19345224
8.

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.

Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, Chen Y, Simpson M, Tsai SP, Dennis MS, Lu Y, Meng YG, Ng C, Yang J, Lee CC, Duenas E, Gorrell J, Katta V, Kim A, McDorman K, Flagella K, Venook R, Ross S, Spencer SD, Lee Wong W, Lowman HB, Vandlen R, Sliwkowski MX, Scheller RH, Polakis P, Mallet W.

Nat Biotechnol. 2008 Aug;26(8):925-32. doi: 10.1038/nbt.1480. Epub 2008 Jul 20.

PMID:
18641636
9.

Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs.

Junutula JR, Bhakta S, Raab H, Ervin KE, Eigenbrot C, Vandlen R, Scheller RH, Lowman HB.

J Immunol Methods. 2008 Mar 20;332(1-2):41-52. doi: 10.1016/j.jim.2007.12.011. Epub 2008 Jan 14.

PMID:
18230399
10.

Therapeutic anti-VEGF antibodies.

Lien S, Lowman HB.

Handb Exp Pharmacol. 2008;(181):131-50. Review.

PMID:
18071944
11.

A substrate-phage approach for investigating caspase specificity.

Lien S, Pastor R, Sutherlin D, Lowman HB.

Protein J. 2004 Aug;23(6):413-25.

PMID:
15517988
12.

Convergent recognition of the IgE binding site on the high-affinity IgE receptor.

Stamos J, Eigenbrot C, Nakamura GR, Reynolds ME, Yin J, Lowman HB, Fairbrother WJ, Starovasnik MA.

Structure. 2004 Jul;12(7):1289-301.

13.

Therapeutic peptides.

Lien S, Lowman HB.

Trends Biotechnol. 2003 Dec;21(12):556-62. Review. No abstract available.

PMID:
14624865
14.

Redesigning an antibody fragment for faster association with its antigen.

Marvin JS, Lowman HB.

Biochemistry. 2003 Jun 17;42(23):7077-83.

PMID:
12795603
15.

Sequence plasticity in the antigen-binding site of a therapeutic anti-HER2 antibody.

Gerstner RB, Carter P, Lowman HB.

J Mol Biol. 2002 Aug 30;321(5):851-62.

PMID:
12206766
16.

Selective alpha4beta7 integrin antagonists and their potential as antiinflammatory agents.

Dubree NJ, Artis DR, Castanedo G, Marsters J, Sutherlin D, Caris L, Clark K, Keating SM, Beresini MH, Chiu H, Fong S, Lowman HB, Skelton NJ, Jackson DY.

J Med Chem. 2002 Aug 1;45(16):3451-7.

PMID:
12139455
17.

Increases in free, unbound insulin-like growth factor I enhance insulin responsiveness in human hepatoma G2 cells in culture.

Sakai K, Lowman HB, Clemmons DR.

J Biol Chem. 2002 Apr 19;277(16):13620-7. Epub 2002 Feb 7.

18.

Stable "zeta" peptides that act as potent antagonists of the high-affinity IgE receptor.

Nakamura GR, Reynolds ME, Chen YM, Starovasnik MA, Lowman HB.

Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1303-8.

19.

A novel family of hairpin peptides that inhibit IgE activity by binding to the high-affinity IgE receptor.

Nakamura GR, Starovasnik MA, Reynolds ME, Lowman HB.

Biochemistry. 2001 Aug 21;40(33):9828-35.

PMID:
11502176
20.

Structure-function analysis of a phage display-derived peptide that binds to insulin-like growth factor binding protein 1.

Skelton NJ, Chen YM, Dubree N, Quan C, Jackson DY, Cochran A, Zobel K, Deshayes K, Baca M, Pisabarro MT, Lowman HB.

Biochemistry. 2001 Jul 24;40(29):8487-98.

PMID:
11456486
21.

Binding protein-3-selective insulin-like growth factor I variants: engineering, biodistributions, and clearance.

Dubaquié Y, Mortensen DL, Intintoli A, Hogue DA, Nakamura G, Rancatore P, Lester P, Sadick MD, Filvaroff E, Fielder PJ, Lowman HB.

Endocrinology. 2001 Jan;142(1):165-73.

PMID:
11145579
22.

Phage display for selection of novel binding peptides.

Sidhu SS, Lowman HB, Cunningham BC, Wells JA.

Methods Enzymol. 2000;328:333-63. No abstract available.

PMID:
11075354
23.

A neutralizing monoclonal antibody specific for the dimer interface region of IL-8.

Deforge LE, Lowman HB, Leong SR, Chuntharapai A, Jin Kim K, Hébert CA.

Cytokine. 2000 Nov;12(11):1620-9.

PMID:
11052812
24.

Anticalins versus antibodies: made-to-order binding proteins for small molecules.

Weiss GA, Lowman HB.

Chem Biol. 2000 Aug;7(8):R177-84. Review.

25.

FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family.

Holcomb IN, Kabakoff RC, Chan B, Baker TW, Gurney A, Henzel W, Nelson C, Lowman HB, Wright BD, Skelton NJ, Frantz GD, Tumas DB, Peale FV Jr, Shelton DL, Hébert CC.

EMBO J. 2000 Aug 1;19(15):4046-55.

26.

Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen.

Chen Y, Wiesmann C, Fuh G, Li B, Christinger HW, McKay P, de Vos AM, Lowman HB.

J Mol Biol. 1999 Nov 5;293(4):865-81.

PMID:
10543973
28.

VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface.

Muller YA, Chen Y, Christinger HW, Li B, Cunningham BC, Lowman HB, de Vos AM.

Structure. 1998 Sep 15;6(9):1153-67.

29.

Molecular mimics of insulin-like growth factor 1 (IGF-1) for inhibiting IGF-1: IGF-binding protein interactions.

Lowman HB, Chen YM, Skelton NJ, Mortensen DL, Tomlinson EE, Sadick MD, Robinson IC, Clark RG.

Biochemistry. 1998 Jun 23;37(25):8870-8.

PMID:
9636028
30.

Phage display of peptide libraries on protein scaffolds.

Lowman HB.

Methods Mol Biol. 1998;87:249-64. No abstract available.

PMID:
9523276
31.
32.

IL-8 single-chain homodimers and heterodimers: interactions with chemokine receptors CXCR1, CXCR2, and DARC.

Leong SR, Lowman HB, Liu J, Shire S, Deforge LE, Gillece-Castro BL, McDowell R, Hébert CA.

Protein Sci. 1997 Mar;6(3):609-17.

33.

Monomeric variants of IL-8: effects of side chain substitutions and solution conditions upon dimer formation.

Lowman HB, Fairbrother WJ, Slagle PH, Kabakoff R, Liu J, Shire S, Hébert CA.

Protein Sci. 1997 Mar;6(3):598-608.

34.

Molecular approaches to structure-function analysis of interleukin-8.

Fairbrother WJ, Lowman HB.

Methods Enzymol. 1997;287:45-58. No abstract available.

PMID:
9330314
35.

Bacteriophage display and discovery of peptide leads for drug development.

Lowman HB.

Annu Rev Biophys Biomol Struct. 1997;26:401-24. Review.

PMID:
9241425
36.

Exchanging interleukin-8 and melanoma growth-stimulating activity receptor binding specificities.

Lowman HB, Slagle PH, DeForge LE, Wirth CM, Gillece-Castro BL, Bourell JH, Fairbrother WJ.

J Biol Chem. 1996 Jun 14;271(24):14344-52.

37.

The stoichiometry of growth hormone-binding protein complexes in human plasma: comparison with cell surface receptors.

Baumann G, Lowman HB, Mercado M, Wells JA.

J Clin Endocrinol Metab. 1994 May;78(5):1113-8.

PMID:
8175967
38.

Affinity maturation of human growth hormone by monovalent phage display.

Lowman HB, Wells JA.

J Mol Biol. 1993 Dec 5;234(3):564-78.

PMID:
8254660
39.

The molecular basis for growth hormone-receptor interactions.

Wells JA, Cunningham BC, Fuh G, Lowman HB, Bass SH, Mulkerrin MG, Ultsch M, deVos AM.

Recent Prog Horm Res. 1993;48:253-75. Review.

PMID:
8441850
40.

Rapid evolution of peptide and protein binding properties in vitro.

Wells JA, Lowman HB.

Curr Opin Biotechnol. 1992 Aug;3(4):355-62. Review.

PMID:
1368436
41.

Selecting high-affinity binding proteins by monovalent phage display.

Lowman HB, Bass SH, Simpson N, Wells JA.

Biochemistry. 1991 Nov 12;30(45):10832-8.

PMID:
1932005
42.

Mutational analysis and protein engineering of receptor-binding determinants in human placental lactogen.

Lowman HB, Cunningham BC, Wells JA.

J Biol Chem. 1991 Jun 15;266(17):10982-8.

44.
45.

On the recognition of helical RNA by cobra venom V1 nuclease.

Lowman HB, Draper DE.

J Biol Chem. 1986 Apr 25;261(12):5396-403.

Supplemental Content

Loading ...
Support Center